EGFR-TKI ADR Management Chinese Expert Consensus.
10.3779/j.issn.1009-3419.2019.02.01
- Author:
Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
1
Author Information
1. Department of Oncology, Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200030, China.
- Collective Name:Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
- Publication Type:Journal Article
- Keywords:
Adverse drug reaction;
Consensus;
EGFR-TKI;
Lung neoplasms
- MeSH:
Antineoplastic Agents;
adverse effects;
therapeutic use;
Carcinoma, Non-Small-Cell Lung;
drug therapy;
enzymology;
genetics;
China;
Diarrhea;
etiology;
ErbB Receptors;
antagonists & inhibitors;
genetics;
metabolism;
Humans;
Liver Diseases;
etiology;
Lung Diseases;
etiology;
Lung Neoplasms;
drug therapy;
enzymology;
genetics;
Protein Kinase Inhibitors;
adverse effects;
therapeutic use;
Stomatitis;
etiology
- From:
Chinese Journal of Lung Cancer
2019;22(2):57-81
- CountryChina
- Language:Chinese
-
Abstract:
ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China. And osimertinib was approved in second line setting for patients with EGFRT 790M-positive NSCLC. Rash, paronychia, diarrhea, stomatitis, liver dysfunction and (interstitial lung disease, ILD) are frequently observed in patients treated with EGFR-TKI. Chinese Society of Lung Cancer, Chinese Anti-Cancer Association, organized Chinese experts to develop the Chinese expert consensus on EGFR-TKI adverse event (AE) management based on domestic diagnosis and treatment of ADR and also incorporating international updated theory and recommendations.
.
